info
genetics
finemap-colocalisation
expression
proteomics
metabolomics
multi-omics
MR
PGS
statistics
interaction
other
ml
cancer
Papers
Papers
Gastric cancer: from biomarkers to functional precision medicine
Deep profiling of gene expression across 18 human cancers
Categories
All
(2)
biomarkers
(1)
cancer genomics
(1)
deep learning
(1)
drug development
(1)
gastric cancer
(1)
gene expression
(1)
immunogenomics
(1)
immunotherapy
(1)
oncology
(1)
pan-cancer analysis
(1)
precision medicine
(1)
survival analysis
(1)
targeted therapy
(1)
tcga subtypes
(1)
variational autoencoder
(1)
cancer
Deep profiling of gene expression across 18 human cancers
Framework:
This paper introduces
DeepProfile
, an unsupervised deep-learning model using an
ensemble of Variational Autoencoders (VAEs)
to create robust and biologically interpretable low-dimensional latent spaces from 50,211 transcriptomes across 18 human cancers.
Key Biological Findings:
Universal latent variables across all 18 cancers are driven by genes controlling
immune cell activation
, while cancer-specific variables define molecular subtypes.
Clinical Associations:
DeepProfile linked gene expression to clinical outcomes, finding that Tumour Mutation Burden (TMB) is associated with
cell-cycle pathways
, and patient survival correlates with
DNA-mismatch repair
and
MHC class II antigen presentation
pathway activity.
23 January 2026
Gastric cancer: from biomarkers to functional precision medicine
Current Landscape:
Treatment for advanced gastric cancer is rapidly evolving beyond chemotherapy, with approved targeted agents including Trastuzumab (HER2), Zolbetuximab (CLDN18.2), and Pembrolizumab/Nivolumab (PD-L1).
Emerging Targets:
Key areas of development include novel Antibody-Drug Conjugates (ADCs), the anti-FGFR2b antibody Bemarituzumab, and bispecific antibodies to overcome resistance mechanisms and improve response rates.
Precision Medicine Goal:
The future of GC therapy relies on integrating multi-omics analysis (biomarkers) with
functional drug testing
on patient-derived models (organoids) to enable individualized treatment selection and improve patient survival.
23 January 2026
No matching items